BB's Stock Haven

[budfoxfun]

$NBIO Analysts suggest Nascent Value at $0.60 to $2.84 per share - NORTH PALM BEACH, FL / ACCESSWIRE / January 9, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies focused on treating various cancers, announced today that the Company was featured in an independent research report by Marble Arch Research


The report can be viewed on the Company web site at: https://www.nascentbiotech.com/marble-arch-research-what-is-pritumumab-and-how-it-works/

Nascent CEO Sean Carrick remarked, "We are pleased to be featured in this independent prospective of Nascent's investment potential. This report underscores our internal conviction that the Company's common stock is presently undervalued."

Management highlights the research as corroborating its own sense that Pritumumab (PTB) is a potential breakthrough therapy in the $1.8 billion underserved brain cancer market. PTB has demonstrated safety and efficacy as well as a capacity to breach the blood-brain barrier to attack brain cancer cells.